Poster 18
- Jun 17, 2023
- 1 min read
Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: First year of ADlong Long-Term Extension Trial
Stephan Weidinger, Alan Irvine, Diamant Thaçi, Jacek C Szepietowski, Tilo Biedermann, Helena Agell, Yanislav Mihaylov, Belchin Kostov, Ruth Coll, William Romero, Kristian Reich


